Clinical Focus

  • Pediatrics
  • Hospital Medicine
  • Children with Special Health Care Needs
  • Shared Decision Making

Academic Appointments

Honors & Awards

  • KL2 Mentored Career Development Award (NIH KL2 TR 001083), Stanford Center for Clinical and Translational Research and Education (Spectrum) (2016)

Boards, Advisory Committees, Professional Organizations

  • Member, American Academy of Pediatrics (2011 - Present)
  • Member, Academic Pediatrics Association (2014 - Present)
  • Member, Society for Pediatric Research (2016 - Present)
  • Member, Society of Medical Decision Making (2017 - Present)

Professional Education

  • Fellowship:Stanford Pediatric Hospital Medicine Fellowship (2016) CA
  • Medical Education:University of California at Irvine School of Medicine Registrar (2011) CA
  • Residency:Baylor College of Medicine (2014) TX
  • Fellowship, Stanford University - Clinical Excellence Research Center, Health Systems Design (2016)
  • Board Certification: Pediatrics, American Board of Pediatrics (2014)

Current Research and Scholarly Interests

Jody Lin, MD received her BS in Chemical Biology with a minor in Public Policy at UC Berkeley followed by her MD at UC Irvine. She then completed her general pediatrics residency at Baylor College of Medicine before coming to Stanford to complete concurrent fellowships in Pediatric Hospital Medicine at the Department of Pediatrics and Health Systems Design at the Clinical Excellence Research Center (CERC).

Dr. Lin is currently a Spectrum KL2 Career Development Award scholar through which she will complete a Masters in Health Services Research and pursue further research in shared decision making and health systems design for children with medical complexity. Current projects include exploring narratives of parents of children with medical complexity, developing technological aids for chronic illness management, and piloting new models of care in early childhood.

Dr. Lin has volunteered for and led multiple initiatives providing medical services to resource-limited populations, most notably partnering with county public health programs and nonprofits to provide wraparound services to combat generational homelessness. Subsequently she became interested in program evaluation using health services research methodologies and has focused on improving care for vulnerable populations in pediatrics, such as children with medical complexity. She was also part of a multidisciplinary team that created new models of care to improve health care value in early childhood at CERC.

All Publications

  • Shared decision making among children with medical complexity: results from a population-based survey The Journal of Pediatrics Lin, J. L., Cohen, E., Sanders, L. M. 2018
  • Well-Appearing Newborn with Vesiculobullous Rash at Birth Pediatrics Steward, S., Lin, J. L., Everhart, J., Pham, T., Marqueling, A., Hilgenberg, S. 2018; 141 (3)
  • Does Routine Imaging of Patients for Progression or Relapse Improve Survival in Rhabdomyosarcoma? PEDIATRIC BLOOD & CANCER Lin, J. L., Guillerman, R. P., Russell, H. V., Lupo, P. J., Nicholls, L., Okcu, M. F. 2016; 63 (2): 202-205


    Patients with rhabdomyosarcoma (RMS) who complete therapy typically undergo 4 years of surveillance imaging despite lack of evidence that this improves outcomes. We compared overall survival (OS) between patients in whom progression or relapse was detected by routine clinical evaluation or by imaging.Children with progressive or relapsed RMS treated at Texas Children's Hospital between 1992 and 2012 were identified and their records were reviewed. Survival time after progression or relapse was compared between two groups: (1) patients in whom progression or relapse was suspected on the basis of clinical history, symptoms, laboratory evaluation, or physical exam; and (2) patients whose progression or relapse was initially detected by imaging.Of the 43 children with progressive or relapsed RMS, 26 (60%) had metastatic disease at diagnosis and 19 (44%) had alveolar histology. With a median follow up time of 5 years in six survivors, there was no difference in OS between patients in whom progression or relapse was diagnosed based on imaging (n = 15) or by clinical evaluation (n = 28) (3-year OS 20% vs. 11%, respectively, P = 0.38). Disease extent, primary site, and risk group at diagnosis were associated with survival after progression or relapse.Routine surveillance imaging practice should be critically reviewed for children with RMS. Although our findings must be validated by larger studies, they do have substantive implications. Reduced imaging tailored to the risk and pattern of recurrence, associated risks and cost could improve patient quality of life and decrease health-care expenditure without compromising outcome.

    View details for DOI 10.1002/pbc.25750

    View details for Web of Science ID 000370248900004

    View details for PubMedID 26376023